Wu Xiaohui of Wanhuida Intellectual Property examines how a recent CNIPA decision reinforces the need for a holistic inventive step assessment when evaluating pharmaceutical combination formulations ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback